​

Tecelra (FKA Afami-Cell) - Afamitresgene autoleucel manufactured by Adaptimmune received accelerated approval from the FDA on August 6, 2024. The wholesale acquisition price for the cell therapy only is 727K. The risk threshold for the therapy (the highest you should expect to pay) is $1.4 million.

 

 The anticipated cost of therapy plus administration, with no complications, is 950K-1 million. It is the first engineered cell therapy to receive approval for a solid tumor and the first T cell receptor (TCR) therapy to enter the U.S. market.